Osteoblasts for Inflammatory Rheumatic Disease Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory rheumatic diseases (IRD) lack effective modalities targeting the inflammatory component, with existing therapies primarily focusing on symptom relief rather than addressing the underlying inflammation and bone lesions.

Innovation Solution

The use of isolated osteoblasts, derived from bone marrow stem cells or mesenchymal stem cells, which exhibit potent immunosuppressive and anti-inflammatory actions, for the treatment of IRD, either alone or in combination with disease-modifying antirheumatic drugs and glucocorticoids, to suppress inflammation and promote bone regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (DMARD, glucocorticoids, NSAID) are used for IRD, then symptom relief is achieved, but the inflammatory component and underlying pathology are not effectively targeted

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidinflammatory component

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Osteoblasts serve as intermediary cells that mediate between the inflammatory environment and tissue repair processes. These bone-forming cells are administered to patients with inflammatory rheumatic diseases to directly suppress inflammation and promote bone regeneration, acting as a biological bridge between immune modulation and tissue repair that conventional drugs cannot achieve simultaneously

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If existing therapies focus on symptom relief, then immediate comfort is provided, but underlying inflammation and bone lesions remain unaddressed

Engineering Contradiction:

Improvesymptom reliefVSAvoidbone lesions

Core Design Contradiction:

Ease of operationVSObject-generated harmful factors

Solution Approach 1:

The invention merges two previously separate therapeutic goals into a single treatment approach: anti-inflammatory action and bone regeneration. Osteoblasts are used to simultaneously address both the inflammatory component and bone lesions in inflammatory rheumatic diseases, combining functions that were previously achieved through separate symptomatic treatments and disease-modifying therapies

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentEP2224934B1Use of osteoblasts in the treatment of inflammatory rheumatic diseases

Publication Date: 2012.08.15 BONE THRAPEUTICS SA

Figure 1
Figure 2
Figure 3

AI summary

The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases.